{"success":true,"data":{"pressRelease":{"id":"20859","rtpr_id":"nBw1N2fSqa","ticker":"ENVB","exchange":"NASDAQ","all_tickers":["ENVB"],"title":"Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model","author":"Business Wire","published_at":"2026-05-05T12:00:00.416Z","article_body":"Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical\nModel\n\nPreviously reported results support continued development of EB-003 for PTSD\nand other neuropsychiatric conditions\n\nRecent U.S. Executive Order supporting psychedelic-inspired therapies\nhighlights growing focus on PTSD and reinforces opportunity for\nneuroplastogens such as EB-003\n\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a\nbiotechnology company advancing novel neuroplastogenic small-molecule\ntherapeutics to address psychiatric and neurological disorders, today\nhighlighted preclinical data for its lead candidate, EB-003, a dual 5-HT(2A)\nand 5-HT(1B) modulator, in which a single dose of EB-003 significantly reduced\ncontext-induced freezing behavior one hour post-dose (p < 0.05). These\nresults indicate a rapid reduction in conditioned fear response in a validated\npreclinical model of post-traumatic stress disorder (PTSD).\n\nPresident Donald Trump’s April 18, 2026, Executive Order supporting research\ninto psychedelic therapies for mental health conditions, including PTSD,\nhighlights increasing recognition at the federal level of the urgent need for\nnovel treatment approaches. President Trump stated, “In many cases, these\nexperimental treatments have shown life-changing potential for those suffering\nfrom severe mental illness and depression.” Secretary of Health and Human\nServices Robert F. Kennedy Jr commented, “At the same time, millions of\nAmericans living with depression, PTSD, addiction and other conditions do not\nrespond to existing treatments.”\n\nJoseph Tucker, Ph.D., CEO of Enveric Biosciences, stated: “We believe\nEnveric’s portfolio of neuroplastogenic compounds, such as EB-003, is well\npositioned to meet the challenges recognized by regulators and provide\ntherapeutic solutions that fit within existing patient treatment approaches\nwhile avoiding real-world limitations of delivering traditional hallucinogenic\npsychedelic therapies, which may require specialized clinical\ninfrastructure.”\n\n“Enveric’s EB-003 findings in a model of PTSD highlight the potential\nimportance of targeting both neuroplasticity and mood signaling pathways,”\nDr. Tucker continued. “We believe EB-003’s combined activity at 5-HT(2A)\nand 5-HT(1B) receptors may offer a differentiated approach to promoting\nneuroplasticity while restoring key signaling pathways involved in emotional\nregulation and stress response.”\n\nEB-003 is designed as a next-generation neuroplastogen that combines partial\nagonism at the 5-HT(2A) receptor with concomitant agonism of the 5-HT(1B)\nreceptor. Prior studies have reported that reduced 5-HT(1B) receptor\nexpression and function in key brain regions is associated with increased\nseverity of PTSD symptoms, enhanced comorbidity with major depressive\ndisorder, and greater lifetime trauma burden. Activation of 5-HT(2A) receptors\nhas been associated with increased neuroplasticity in brain regions involved\nin cognition, emotional regulation and decision making. Together, these\nmechanisms may enable differentiated therapeutic benefit in PTSD and other\nneuropsychiatric disorders.\n\nAbout Enveric Biosciences\n\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on\ndeveloping next-generation, small-molecule neuroplastogenic therapeutics that\naddress unmet needs in psychiatric and neurological disorders. By leveraging a\ndifferentiated drug discovery platform and a growing library of protected\nchemical structures, Enveric is advancing a pipeline of novel compounds\ndesigned to promote neuroplasticity without hallucinogenic effects.\nEnveric’s lead candidate, EB-003, is the first known compound designed to\nselectively engage both 5-HT(2A) and 5-HT(1B) receptors to deliver\nfast-acting, durable antidepressant and anxiolytic effects with outpatient\nconvenience.\n\nFor more information, please visit www.enveric.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enveric.com&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=www.enveric.com&index=1&md5=d12a11769cac0fd130ae528fd8297f69)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements and forward-looking\ninformation within the meaning of applicable securities laws. These statements\nrelate to future events or future performance. All statements other than\nstatements of historical fact may be forward-looking statements or\ninformation. Generally, forward-looking statements and information may be\nidentified by the use of forward-looking terminology such as \"plans,\"\n\"expects\" or \"does not expect,\" \"proposes,\" \"budgets,\" \"explores,\"\n\"schedules,\" \"seeks,\" \"estimates,\" \"forecasts,\" \"intends,\" \"anticipates\" or\n\"does not anticipate,\" or \"believes,\" or variations of such words and phrases,\nor by the use of words or phrases which state that certain actions, events or\nresults may, could, should, would, or might occur or be achieved.\nForward-looking statements may include statements regarding beliefs, plans,\nexpectations, or intentions regarding the future and are based on the beliefs\nof management as well as assumptions made by and information currently\navailable to management. Actual results could differ materially from those\ncontemplated by the forward-looking statements as a result of certain factors,\nincluding, but not limited to, the ability of Enveric to: finalize and submit\nits IND application to the U.S. Food and Drug Administration; carry out\nsuccessful clinical programs; achieve the value creation contemplated by\ntechnical developments; avoid delays in planned clinical trials; establish\nthat potential products are efficacious or safe in preclinical or clinical\ntrials; establish or maintain collaborations for the development of\ntherapeutic candidates; obtain appropriate or necessary governmental approvals\nto market potential products; obtain future funding for product development\nand working capital on commercially reasonable terms; scale-up manufacture of\nproduct candidates; respond to changes in the size and nature of competitors;\nhire and retain key executives and scientists; secure and enforce legal rights\nrelated to Enveric’s products, including patent protection; identify and\npursue alternative routes to capture value from its research and development\npipeline assets; continue as a going concern; and manage its future growth\neffectively.\n\nA discussion of these and other factors, including risks and uncertainties\nwith respect to Enveric, is set forth in Enveric’s filings with the\nSecurities and Exchange Commission, including Enveric’s Annual Report on\nForm 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any\nintention or obligation to revise any forward-looking statements, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260505587393/en/\n(https://www.businesswire.com/news/home/20260505587393/en/)\n\nInvestor Relations \n\nTiberend Strategic Advisors, Inc. \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftiberend.com%2F&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=Tiberend+Strategic+Advisors%2C+Inc.&index=2&md5=115f709d7207fc56a06d400ec3199c55)\n\nDavid Irish\n\n(231) 632-0002\n\ndirish@tiberend.com (mailto:dirish@tiberend.com)\n\nMedia Relations \n\nTiberend Strategic Advisors, Inc. \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftiberend.com%2F&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=Tiberend+Strategic+Advisors%2C+Inc.&index=3&md5=cb09085903e0533416b62bbf7b0ad78b)\n\nCasey McDonald\n\n(646) 577-8520\n\ncmcdonald@tiberend.com (mailto:cmcdonald@tiberend.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1N2fSqa","title":"Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model","author":"Business Wire","ticker":"ENVB","created":"2026-05-05T12:00:00.416Z","tickers":["ENVB"],"exchange":"NASDAQ","article_body":"Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical\nModel\n\nPreviously reported results support continued development of EB-003 for PTSD\nand other neuropsychiatric conditions\n\nRecent U.S. Executive Order supporting psychedelic-inspired therapies\nhighlights growing focus on PTSD and reinforces opportunity for\nneuroplastogens such as EB-003\n\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a\nbiotechnology company advancing novel neuroplastogenic small-molecule\ntherapeutics to address psychiatric and neurological disorders, today\nhighlighted preclinical data for its lead candidate, EB-003, a dual 5-HT(2A)\nand 5-HT(1B) modulator, in which a single dose of EB-003 significantly reduced\ncontext-induced freezing behavior one hour post-dose (p < 0.05). These\nresults indicate a rapid reduction in conditioned fear response in a validated\npreclinical model of post-traumatic stress disorder (PTSD).\n\nPresident Donald Trump’s April 18, 2026, Executive Order supporting research\ninto psychedelic therapies for mental health conditions, including PTSD,\nhighlights increasing recognition at the federal level of the urgent need for\nnovel treatment approaches. President Trump stated, “In many cases, these\nexperimental treatments have shown life-changing potential for those suffering\nfrom severe mental illness and depression.” Secretary of Health and Human\nServices Robert F. Kennedy Jr commented, “At the same time, millions of\nAmericans living with depression, PTSD, addiction and other conditions do not\nrespond to existing treatments.”\n\nJoseph Tucker, Ph.D., CEO of Enveric Biosciences, stated: “We believe\nEnveric’s portfolio of neuroplastogenic compounds, such as EB-003, is well\npositioned to meet the challenges recognized by regulators and provide\ntherapeutic solutions that fit within existing patient treatment approaches\nwhile avoiding real-world limitations of delivering traditional hallucinogenic\npsychedelic therapies, which may require specialized clinical\ninfrastructure.”\n\n“Enveric’s EB-003 findings in a model of PTSD highlight the potential\nimportance of targeting both neuroplasticity and mood signaling pathways,”\nDr. Tucker continued. “We believe EB-003’s combined activity at 5-HT(2A)\nand 5-HT(1B) receptors may offer a differentiated approach to promoting\nneuroplasticity while restoring key signaling pathways involved in emotional\nregulation and stress response.”\n\nEB-003 is designed as a next-generation neuroplastogen that combines partial\nagonism at the 5-HT(2A) receptor with concomitant agonism of the 5-HT(1B)\nreceptor. Prior studies have reported that reduced 5-HT(1B) receptor\nexpression and function in key brain regions is associated with increased\nseverity of PTSD symptoms, enhanced comorbidity with major depressive\ndisorder, and greater lifetime trauma burden. Activation of 5-HT(2A) receptors\nhas been associated with increased neuroplasticity in brain regions involved\nin cognition, emotional regulation and decision making. Together, these\nmechanisms may enable differentiated therapeutic benefit in PTSD and other\nneuropsychiatric disorders.\n\nAbout Enveric Biosciences\n\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on\ndeveloping next-generation, small-molecule neuroplastogenic therapeutics that\naddress unmet needs in psychiatric and neurological disorders. By leveraging a\ndifferentiated drug discovery platform and a growing library of protected\nchemical structures, Enveric is advancing a pipeline of novel compounds\ndesigned to promote neuroplasticity without hallucinogenic effects.\nEnveric’s lead candidate, EB-003, is the first known compound designed to\nselectively engage both 5-HT(2A) and 5-HT(1B) receptors to deliver\nfast-acting, durable antidepressant and anxiolytic effects with outpatient\nconvenience.\n\nFor more information, please visit www.enveric.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enveric.com&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=www.enveric.com&index=1&md5=d12a11769cac0fd130ae528fd8297f69)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements and forward-looking\ninformation within the meaning of applicable securities laws. These statements\nrelate to future events or future performance. All statements other than\nstatements of historical fact may be forward-looking statements or\ninformation. Generally, forward-looking statements and information may be\nidentified by the use of forward-looking terminology such as \"plans,\"\n\"expects\" or \"does not expect,\" \"proposes,\" \"budgets,\" \"explores,\"\n\"schedules,\" \"seeks,\" \"estimates,\" \"forecasts,\" \"intends,\" \"anticipates\" or\n\"does not anticipate,\" or \"believes,\" or variations of such words and phrases,\nor by the use of words or phrases which state that certain actions, events or\nresults may, could, should, would, or might occur or be achieved.\nForward-looking statements may include statements regarding beliefs, plans,\nexpectations, or intentions regarding the future and are based on the beliefs\nof management as well as assumptions made by and information currently\navailable to management. Actual results could differ materially from those\ncontemplated by the forward-looking statements as a result of certain factors,\nincluding, but not limited to, the ability of Enveric to: finalize and submit\nits IND application to the U.S. Food and Drug Administration; carry out\nsuccessful clinical programs; achieve the value creation contemplated by\ntechnical developments; avoid delays in planned clinical trials; establish\nthat potential products are efficacious or safe in preclinical or clinical\ntrials; establish or maintain collaborations for the development of\ntherapeutic candidates; obtain appropriate or necessary governmental approvals\nto market potential products; obtain future funding for product development\nand working capital on commercially reasonable terms; scale-up manufacture of\nproduct candidates; respond to changes in the size and nature of competitors;\nhire and retain key executives and scientists; secure and enforce legal rights\nrelated to Enveric’s products, including patent protection; identify and\npursue alternative routes to capture value from its research and development\npipeline assets; continue as a going concern; and manage its future growth\neffectively.\n\nA discussion of these and other factors, including risks and uncertainties\nwith respect to Enveric, is set forth in Enveric’s filings with the\nSecurities and Exchange Commission, including Enveric’s Annual Report on\nForm 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any\nintention or obligation to revise any forward-looking statements, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260505587393/en/\n(https://www.businesswire.com/news/home/20260505587393/en/)\n\nInvestor Relations \n\nTiberend Strategic Advisors, Inc. \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftiberend.com%2F&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=Tiberend+Strategic+Advisors%2C+Inc.&index=2&md5=115f709d7207fc56a06d400ec3199c55)\n\nDavid Irish\n\n(231) 632-0002\n\ndirish@tiberend.com (mailto:dirish@tiberend.com)\n\nMedia Relations \n\nTiberend Strategic Advisors, Inc. \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftiberend.com%2F&esheet=54528402&newsitemid=20260505587393&lan=en-US&anchor=Tiberend+Strategic+Advisors%2C+Inc.&index=3&md5=cb09085903e0533416b62bbf7b0ad78b)\n\nCasey McDonald\n\n(646) 577-8520\n\ncmcdonald@tiberend.com (mailto:cmcdonald@tiberend.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-05T12:00:00.458203881Z","server_sent_at_ms":1777982400458},"received_at":"2026-05-05T12:00:00.568Z","source_url":"https://www.businesswire.com/news/home/20260505587393/en/"},"analysis":{"id":"15423","press_release_id":"20859","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["results characterized as 'previously reported' in body text despite 'Highlights Positive Results' headline"],"eventType":"other","narrative":"Enveric Biosciences highlighted previously reported preclinical data for EB-003, showing reduced fear response in a PTSD model, tying the results to President Trump’s recent Executive Order on psychedelic therapies.\n\nCEO Joseph Tucker emphasized that EB-003 is designed to offer therapeutic benefits without the specialized clinical infrastructure required for traditional hallucinogenic therapies.\n\nThe company continues to advance EB-003, a dual 5-HT(2A) and 5-HT(1B) receptor modulator, as a non-hallucinogenic neuroplastogen for psychiatric disorders.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small-cap ties old preclinical data to new Trump EO; no new clinical milestones."},"keyFigures":{"drugName":"EB-003","phaseOfTrial":"preclinical"},"quotedText":"We believe Enveric’s portfolio of neuroplastogenic compounds, such as EB-003, is well positioned to meet the challenges recognized by regulators and provide therapeutic solutions that fit within existing patient treatment approaches while avoiding real-world limitations of delivering traditional hallucinogenic psychedelic therapies","namedEntities":{"people":[{"name":"Joseph Tucker","role":"CEO"},{"name":"Donald Trump","role":"U.S. President"},{"name":"Robert F. Kennedy Jr","role":"Secretary of Health and Human Services"},{"name":"David Irish","role":"Investor Relations Contact"},{"name":"Casey McDonald","role":"Media Relations Contact"}],"products":["EB-003"],"companies":[{"name":"Enveric Biosciences","ticker":"ENVB"},{"name":"Tiberend Strategic Advisors, Inc.","relationship":"IR/PR firm"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The release reiterates previously reported preclinical data for EB-003 in the context of a new Executive Order supporting psychedelic therapies. While the regulatory tailwind is positive, the scientific data is not new and the asset remains preclinical."},"tickerRelevance":{"others":[],"primary":"ENVB"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"rehashed-preclinical-data","sectorWeight":"biotech-niche"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Enveric Biosciences highlighted previously reported preclinical data for EB-003, showing reduced fear response in a PTSD model, tying the results to President Trump’s recent Executive Order on psychedelic therapies.\n\nCEO Joseph Tucker emphasized that EB-003 is designed to offer therapeutic benefits without the specialized clinical infrastructure required for traditional hallucinogenic therapies.\n\nThe company continues to advance EB-003, a dual 5-HT(2A) and 5-HT(1B) receptor modulator, as a non-hallucinogenic neuroplastogen for psychiatric disorders.","key_figures":{"drugName":"EB-003","phaseOfTrial":"preclinical"},"named_entities":{"people":[{"name":"Joseph Tucker","role":"CEO"},{"name":"Donald Trump","role":"U.S. President"},{"name":"Robert F. Kennedy Jr","role":"Secretary of Health and Human Services"},{"name":"David Irish","role":"Investor Relations Contact"},{"name":"Casey McDonald","role":"Media Relations Contact"}],"products":["EB-003"],"companies":[{"name":"Enveric Biosciences","ticker":"ENVB"},{"name":"Tiberend Strategic Advisors, Inc.","relationship":"IR/PR firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-05T13:04:27.586Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"rehashed-preclinical-data","sectorWeight":"biotech-niche"}},"durationMs":147391,"modelName":"glm-4.7"}}